featured
Trastuzumab With Trimodality Treatment for Oesophageal Adenocarcinoma With HER2 Overexpression
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
The Lancet Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Trastuzumab with trimodality treatment for oesophageal adenocarcinoma with HER2 overexpression (NRG Oncology/RTOG 1010): a multicentre, randomised, phase 3 trial
Lancet Oncol 2022 Jan 14;na(na)na, HP Safran, K Winter, DH Ilson, D Wigle, T DiPetrillo, MG Haddock, TS Hong, LP Leichman, L Rajdev, M Resnick, LA Kachnic, S Seaward, H Mamon, DA Diaz Pardo, CM Anderson, X Shen, AK Sharma, AW Katz, J Salo, KL Leonard, J Moughan, CH CraneFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.